Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of “Buy” from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have earned an average recommendation of “Buy” from the seven brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $15.80.

Several brokerages recently issued reports on ZURA. HC Wainwright reiterated a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a research report on Tuesday, December 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th.

Zura Bio Trading Down 1.6 %

Shares of NASDAQ ZURA opened at $1.26 on Monday. The firm’s 50-day simple moving average is $1.73 and its 200 day simple moving average is $2.99. Zura Bio has a 12-month low of $1.10 and a 12-month high of $6.35.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its position in Zura Bio by 51.6% during the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock valued at $58,000 after purchasing an additional 7,828 shares during the period. Wells Fargo & Company MN increased its stake in shares of Zura Bio by 68.6% in the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock valued at $58,000 after acquiring an additional 9,379 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Zura Bio by 37.3% in the 4th quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock valued at $94,000 after acquiring an additional 10,231 shares during the last quarter. Finally, American Century Companies Inc. bought a new stake in shares of Zura Bio in the 4th quarter valued at about $27,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.